SCHEMBL6896024

SCHEMBL6896024

CCOC(CNCC(=O)O)OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.38
EPHX1 P07099 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP2D6 P10635 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ATM Q13315 1/20 0.33
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
PTGS2 P35354 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
FFAR3 O14843 2/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
MME P08473 1/20 0.32
ACE P12821 1/20 0.32
CPA1 P15085 1/20 0.32
ACE2 Q9BYF1 1/20 0.32
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27837628 0.84 EPHX1 (0.36) EPHX1ALDH1A1SMN1; SMN2ATMFFAR3
SCHEMBL3076938 0.82 TET2 (0.36) EPHX1ALDH1A1SMN1; SMN2ATMMAPK1
SCHEMBL6078959 0.80 GAA (0.46) EPHX1ALDH1A1SMN1; SMN2MAPTMGAM
SCHEMBL1852852 0.78 EGLN1 (0.40) EGLN1ALDH1A1CYP2D6SMN1; SMN2LMNA
SCHEMBL8315999 0.77 THRB (0.42) EPHX1ATMLMNA
SCHEMBL7277502 0.76 PTPRC (0.33) EPHX1CYP2D6MAPT
SCHEMBL10008936 0.74 CYP2D6 (0.50) EGLN1EPHX1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL2263311 0.72 KDM4E (0.41) EPHX1LMNA
SCHEMBL7258476 0.71 GABRP (0.50) EGLN1ALDH1A1LMNAFFAR3HDAC3
SCHEMBL24307672 0.71 EPHX1 (0.35) EPHX1ATMLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6680312-B2 FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-01-20 US disclosed
US-20020193382-A1 Sulfonamide derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2002-12-19 US disclosed
US-6403595-B1 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-06-11 US disclosed
CN-1290254-A Sulfonamide derivatives process for producing the same and utilization thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-04-04 CN disclosed
EP-1054005-A1 SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-11-22 EP disclosed
EP-0529858-B1 2-Piperazinone compounds, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-10-15 EP disclosed
US-5294713-A Inhibiting cell adhesion TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-03-15 US disclosed
EP-0529858-A1 2-Piperazinone compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1993-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193382-A1 Sulfonamide derivatives, their production and use F12, F11, F2 EGLN1 614/4885EPHX1 1156/4885ALDH1A1 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.